Published in Free Radic Biol Med on May 08, 2012
Exhaled breath condensate eicosanoid levels associate with asthma and its severity. J Allergy Clin Immunol (2013) 1.59
Lipidomics of oxidized polyunsaturated fatty acids. Free Radic Biol Med (2012) 1.00
Plasma metabolomics in human pulmonary tuberculosis disease: a pilot study. PLoS One (2014) 0.99
Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. Nat Rev Immunol (2015) 0.99
Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation. PLoS One (2013) 0.97
Bioinformatics: the next frontier of metabolomics. Anal Chem (2014) 0.95
Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome. ISME J (2015) 0.93
Sum of the parts: mass spectrometry-based metabolomics. Biochemistry (2013) 0.92
Metabolomic Evaluation of Neutrophilic Airway Inflammation in Cystic Fibrosis. Chest (2015) 0.85
Resolvin D1 and Resolvin E1 Promote the Resolution of Allergic Airway Inflammation via Shared and Distinct Molecular Counter-Regulatory Pathways. Front Immunol (2012) 0.84
Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice. Toxicol Appl Pharmacol (2015) 0.83
Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB J (2017) 0.83
DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation. Eur J Pharmacol (2015) 0.80
CFTR activity and mitochondrial function. Redox Biol (2013) 0.79
Impact of storage conditions on metabolite profiles of sputum samples from persons with cystic fibrosis. J Cyst Fibros (2015) 0.79
Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators. Proc Natl Acad Sci U S A (2016) 0.78
Profiling the Oxylipin and Endocannabinoid Metabolome by UPLC-ESI-MS/MS in Human Plasma to Monitor Postprandial Inflammation. PLoS One (2015) 0.78
Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med (2017) 0.77
Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Aspects Med (2017) 0.76
Redox balance in cystic fibrosis. Int J Biochem Cell Biol (2014) 0.76
Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer. World J Clin Cases (2016) 0.76
Regulation of inflammation by lipid mediators in oral diseases. Oral Dis (2016) 0.75
Biomarkers for cystic fibrosis drug development. J Cyst Fibros (2016) 0.75
Clinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain: An Emerging Therapeutic Target. Pharmaceutics (2017) 0.75
Lessons learned from metabolomics in cystic fibrosis. Mol Cell Pediatr (2015) 0.75
3,3',4,4',5-Pentachlorobiphenyl (PCB 126) Decreases Hepatic and Systemic Ratios of Epoxide to Diol Metabolites of Unsaturated Fatty Acids in Male Rats. Toxicol Sci (2016) 0.75
Heart-lung interaction via infection. Ann Am Thorac Soc (2014) 0.75
Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation. Mol Aspects Med (2017) 0.75
Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis (1983) 10.45
Cystic fibrosis. N Engl J Med (2005) 8.09
Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature (2007) 6.53
Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med (1995) 4.82
Airway mucus function and dysfunction. N Engl J Med (2010) 4.41
Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med (2007) 4.34
Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med (2004) 4.09
Glucocorticoid resistance in inflammatory diseases. Lancet (2009) 3.57
Cellular fatty acid composition of selected Pseudomonas species. Appl Microbiol (1972) 3.28
Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum. J Bacteriol (2007) 3.22
The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU. EMBO J (2003) 3.10
Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med (1997) 3.05
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol (2004) 2.86
ExoU is a potent intracellular phospholipase. Mol Microbiol (2004) 2.71
Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol (2010) 2.16
Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem (2009) 2.16
Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway. J Immunol (2007) 2.07
Old and new generation lipid mediators in acute inflammation and resolution. Prog Lipid Res (2010) 1.95
The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol (2002) 1.85
The Pseudomonas aeruginosa secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator. Infect Immun (2007) 1.78
The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J Immunol (2009) 1.71
Innate immune response in CF airway epithelia: hyperinflammatory? Am J Physiol Cell Physiol (2006) 1.69
Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res (2010) 1.53
Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem J (2012) 1.53
Infection and inflammation in cystic fibrosis: a short review. J Cyst Fibros (2005) 1.53
Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc (2007) 1.49
Involvement of cyclooxygenase-2 and prostaglandins in the molecular pathogenesis of inflammatory lung diseases. Am J Physiol Lung Cell Mol Physiol (2006) 1.40
A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J Immunol (2009) 1.34
The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc Natl Acad Sci U S A (2004) 1.33
Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med (2011) 1.32
Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics (2010) 1.29
Update on gene modifiers in cystic fibrosis. Curr Opin Pulm Med (2008) 1.29
Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol (2004) 1.28
Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc Natl Acad Sci U S A (1986) 1.28
Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia. J Med Genet (2010) 1.26
The association of acetaminophen, aspirin, and ibuprofen with respiratory disease and lung function. Am J Respir Crit Care Med (2005) 1.25
Characterization of phospholipase activity of the Pseudomonas aeruginosa type III cytotoxin, ExoU. J Bacteriol (2005) 1.23
Mediator lipidomics: search algorithms for eicosanoids, resolvins, and protectins. Methods Enzymol (2007) 1.22
Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell Microbiol (2008) 1.22
Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis (1993) 1.20
Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis (1987) 1.17
Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. Mucosal Immunol (2010) 1.14
Oxylipin Signaling: A Distinct Role for the Jasmonic Acid Precursor cis-(+)-12-Oxo-Phytodienoic Acid (cis-OPDA). Front Plant Sci (2012) 1.14
Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients. Biomarkers (2009) 1.10
Leukotrienes in the sputum and urine of cystic fibrosis children. Br J Clin Pharmacol (1990) 1.10
TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells. Am J Respir Cell Mol Biol (2009) 1.08
Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am J Respir Crit Care Med (2005) 1.07
Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa. ISME J (2011) 1.07
Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1. FASEB J (2011) 1.07
Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003. Free Radic Biol Med (2006) 1.06
Immune responses in cystic fibrosis: are they intrinsically defective? Am J Respir Cell Mol Biol (2012) 1.06
Lipid autacoids in inflammation and injury responses: a matter of privilege. Mol Interv (2008) 1.05
Emerging treatments in cystic fibrosis. Drugs (2009) 1.05
Advances in methods for the determination of biologically relevant lipid peroxidation products. Free Radic Res (2010) 1.02
Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol (2010) 1.02
Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU. Cell Microbiol (2005) 1.02
Crystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor. J Bacteriol (2010) 1.01
Functional genomic responses to cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR(delta508) in the lung. J Biol Chem (2006) 0.99
Detection of sputum eicosanoids in cystic fibrosis and in normal saliva by bioassay and radioimmunoassay. Br J Clin Pharmacol (1987) 0.99
Lipid mediators as agonists for the resolution of acute lung inflammation and injury. Am J Respir Cell Mol Biol (2006) 0.99
The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. Discov Med (2010) 0.98
Dysregulated NF-kappaB activation in cystic fibrosis: evidence for a primary inflammatory disorder. Am J Physiol Lung Cell Mol Physiol (2001) 0.98
Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint. J Cyst Fibros (2010) 0.96
Comprehensive lipidomics analysis of bioactive lipids in complex regulatory networks. Anal Chem (2010) 0.96
Anti-inflammatory cytokines in cystic fibrosis lung disease. Eur Respir J (2006) 0.94
Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patients. Clin Chem (2007) 0.94
Lipid mediator profiling in pulmonary disease. Curr Pharm Biotechnol (2011) 0.94
Fatty acid metabolism in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids (2010) 0.91
Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids (2007) 0.90
Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients. J Lipid Res (2011) 0.90
Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis. Eur J Hum Genet (2010) 0.89
DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity. J Lipid Res (2011) 0.89
Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology (2007) 0.89
Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Arch Bronconeumol (2009) 0.89
Lipidomics of polyunsaturated-fatty-acid-derived oxygenated metabolites. Biochem Soc Trans (2011) 0.89
Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulator. Expert Rev Proteomics (2010) 0.89
Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids (2008) 0.89
n-3 Fatty acids uniquely affect anti-microbial resistance and immune cell plasma membrane organization. Chem Phys Lipids (2011) 0.88
Bacterial metabolism of human polymorphonuclear leukocyte-derived arachidonic acid. Infect Immun (1992) 0.88
Biochemical characterization of the oxygenation of unsaturated fatty acids by the dioxygenase and hydroperoxide isomerase of Pseudomonas aeruginosa 42A2. J Biol Chem (2010) 0.86
Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis. Am J Clin Nutr (2009) 0.84
Increased Δ5- and Δ6-desaturase, cyclooxygenase-2, and lipoxygenase-5 expression and activity are associated with fatty acid and eicosanoid changes in cystic fibrosis. Biochim Biophys Acta (2011) 0.84
Increased elongase 6 and Δ9-desaturase activity are associated with n-7 and n-9 fatty acid changes in cystic fibrosis. Lipids (2011) 0.84
Prevalence of dyslipidemia in adults with cystic fibrosis. J Cyst Fibros (2009) 0.83
New therapeutic key for cystic fibrosis: a role for lipoxins. Nat Immunol (2004) 0.82
Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: Focus on myeloperoxidase. Free Radic Res (2010) 0.82
Serum lipoprotein concentrations in cystic fibrosis. Science (1978) 0.81
Molecular targets of omega 3 and conjugated linoleic Fatty acids - "micromanaging" cellular response. Front Physiol (2012) 0.81
Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR. Eur Respir J (2008) 0.80
NMR analysis of neutrophil activation in sputum samples from patients with cystic fibrosis. Magn Reson Med (2004) 0.78
Prostaglandin-endoperoxide synthase genes COX1 and COX2 - novel modifiers of disease severity in cystic fibrosis patients. J Appl Genet (2010) 0.77
Studies on lipoxygenase inhibitors. II. KF8940 (2-n-heptyl-4-hydroxyquinoline-N-oxide), a potent and selective inhibitor of 5-lipoxygenase, produced by Pseudomonas methanica. J Antibiot (Tokyo) (1986) 0.76
Neutrophil unsaturated fatty acid release by GM-CSF is impaired in cystic fibrosis. Lipids Health Dis (2010) 0.76
Mass spectrometry-based metabolomics. Mass Spectrom Rev (2006) 5.23
Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation (2003) 4.36
Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A (2005) 4.07
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension (2002) 3.66
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov (2009) 3.46
Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol (2005) 3.38
Metabolomics: building on a century of biochemistry to guide human health. Metabolomics (2005) 3.01
Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res (2004) 2.98
Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res (2005) 2.95
Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol (2002) 2.86
An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension (2005) 2.76
Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol (2004) 2.59
Regulation of ceramide biosynthesis by TOR complex 2. Cell Metab (2008) 2.57
Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem (2007) 2.45
Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem (2004) 2.43
Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab (2007) 2.41
Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res (2006) 2.33
The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res (2002) 2.32
Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal Biochem (2005) 2.26
Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A (2005) 2.25
Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol (2007) 2.17
Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem (2009) 2.16
The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci U S A (2003) 2.13
Differential regulation of dual NADPH oxidases/peroxidases, Duox1 and Duox2, by Th1 and Th2 cytokines in respiratory tract epithelium. FEBS Lett (2005) 2.13
The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A (2005) 2.10
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A (2006) 2.07
Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat (2006) 2.03
Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol (2012) 2.01
Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension (2005) 2.01
The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol (2007) 1.99
Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem (2006) 1.95
Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A (2006) 1.95
Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci U S A (2004) 1.87
Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol (2010) 1.87
In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: receptor-based bioassay screens. Environ Health Perspect (2008) 1.82
Occurrence of endocrine-disrupting chemicals in indoor dust. Sci Total Environ (2008) 1.81
Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett (2006) 1.77
Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol (2005) 1.76
Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res (2010) 1.76
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Smoking and exposure to environmental tobacco smoke decrease some plasma antioxidants and increase gamma-tocopherol in vivo after adjustment for dietary antioxidant intakes. Am J Clin Nutr (2003) 1.74
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet (2006) 1.74
Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci (2006) 1.71
Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci U S A (2008) 1.69
Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem (2005) 1.69
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol (2009) 1.64
Triclocarban enhances testosterone action: a new type of endocrine disruptor? Endocrinology (2007) 1.63
Nitrolinoleate inhibits platelet activation by attenuating calcium mobilization and inducing phosphorylation of vasodilator-stimulated phosphoprotein through elevation of cAMP. J Biol Chem (2001) 1.61
Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A (2007) 1.60
Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol (2009) 1.60
Nitrolinoleate, a nitric oxide-derived mediator of cell function: synthesis, characterization, and vasomotor activity. Proc Natl Acad Sci U S A (2002) 1.59
An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol (2005) 1.59
Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry (2004) 1.59
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A (2002) 1.51
Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol (2009) 1.49
Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol (2003) 1.49
1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J Med Chem (2010) 1.46
Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A (2011) 1.45
Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc Natl Acad Sci U S A (2011) 1.45
Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol (2008) 1.44
Metabolic profiling of major vitamin D metabolites using Diels-Alder derivatization and ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2008) 1.44
Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma. Am J Respir Crit Care Med (2014) 1.44
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol (2008) 1.42
The Photorhabdus Pir toxins are similar to a developmentally regulated insect protein but show no juvenile hormone esterase activity. FEMS Microbiol Lett (2005) 1.40
Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A (2009) 1.40
Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases. Free Radic Biol Med (2002) 1.40
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet (2008) 1.38
Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther (2010) 1.38
The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol (2013) 1.36
PCB-induced oxidative stress in endothelial cells: modulation by nutrients. Int J Hyg Environ Health (2002) 1.36
Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation (2006) 1.35
Metabolomics--a new exciting field within the "omics" sciences. Environ Health Perspect (2004) 1.35
Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension (2006) 1.34
Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol (2004) 1.34
Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond) (2009) 1.34
A baculovirus-encoded protein tyrosine phosphatase gene induces enhanced locomotory activity in a lepidopteran host. Proc Natl Acad Sci U S A (2005) 1.32
1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem (2007) 1.32
Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension (2002) 1.32
Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids. Protein Sci (2005) 1.32
Investigation of human exposure to triclocarban after showering and preliminary evaluation of its biological effects. Environ Sci Technol (2011) 1.31
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. J Med Chem (2012) 1.30
Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J (2008) 1.30
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther (2011) 1.30
Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A (2010) 1.29
Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. Eur J Pharm Sci (2010) 1.29
QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. J Med Chem (2003) 1.28
Studies in humans using deuterium-labeled alpha- and gamma-tocopherols demonstrate faster plasma gamma-tocopherol disappearance and greater gamma-metabolite production. Free Radic Biol Med (2005) 1.28
A sensitive class specific immunoassay for the detection of pyrethroid metabolites in human urine. Chem Res Toxicol (2004) 1.28
Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J (2008) 1.28
High-throughput pharmacokinetic method: cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis. Anal Chim Acta (2006) 1.26
Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol (2003) 1.25
Microarray immunoassay for phenoxybenzoic acid using polymer encapsulated Eu:Gd2O3 nanoparticles as fluorescent labels. Anal Chem (2005) 1.24
Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol (2007) 1.24
Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorg Med Chem (2006) 1.23
Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol (2009) 1.23
Pyrethroid tolerance in Culex pipiens pipiens var molestus from Marin County, California. Pest Manag Sci (2004) 1.23
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol Cancer Ther (2009) 1.22